US regulators approve Moderna flu vaccine
Vaccine manufacturer Moderna said Wednesday the U.S. Food and Drug Administration (FDA) had approved its new influenza vaccine, nearly six months after the regulator briefly rejected an application for review.
The U.S. Food and Drug Administration (FDA) has approved Moderna's new influenza vaccine, mFLUSIVA, for use in all adults aged 50 and older, according to the company's release. This mRNA-based vaccine, which utilizes a new technology, was initially rejected by FDA regulators in February due to concerns about the clinical trials.
However, after a "constructive" meeting, the FDA reversed its decision. mFLUSIVA is expected to be available in the United States for the 2026-2027 respiratory virus season. The vaccine's approval comes as global health authorities continue to support mRNA technology, which was instrumental in the rapid development of COVID-19 vaccines.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
